NPS Pharmaceuticals to Report First Quarter 2013 Financial Results

  NPS Pharmaceuticals to Report First Quarter 2013 Financial Results

Business Wire

BEDMINSTER, N.J. -- May 01, 2013

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report
its first quarter 2013 financial results on Thursday, May 9, 2013 at
approximately 8:00 a.m. ET. The press release will be followed by a conference
call and webcast at 8:30 a.m. ET.

To participate in the conference call, dial (866) 515-2910 and use passcode
73536235. International callers may dial (617) 399-5124, using the same
passcode. In addition, a live audio of the conference call will be available
over the Internet. Interested parties can access the event through the
investors’ calendar of events page on the NPS website at

If you are unable to participate in the live call, a replay will be available
at (888) 286-8010, with passcode 47948306 until midnight ET, May 23, 2013.
International callers may access the replay by dialing (617) 801-6888, using
the same passcode. The webcast will also be available through the NPS website
for the same period.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering
therapies that transform the lives of patients with rare diseases worldwide.
The company’s lead product, Gattex® (U.S.)/Revestive® (EU) 0.05 mg/kg/d
(teduglutide [rDNA origin]) for injection is approved for adult short bowel
syndrome (SBS). NPS is also developing Natpara® (rhPTH[1-84]) for the
treatment of adult hypoparathyroidism and, subject to the resolution of
certain manufacturing issues, expects to submit its Biologic License
Application (BLA) to the FDA in 2013. NPS's earlier stage pipeline includes
two calcilytic compounds, NPSP790 and NPSP795, with potential application in
rare disorders involving increased calcium receptor activity, such as
autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements
its proprietary programs with a royalty-based portfolio of products and
product candidates that includes agreements with Amgen, GlaxoSmithKline,
Janssen Pharmaceuticals and Kyowa Hakko Kirin.


NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335
Press spacebar to pause and continue. Press esc to stop.